Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab plus Axitinib in Advanced GIST
NCT04258956Phase 2Completed
- Sponsor
- Maria Skłodowska-Curie National Research Institute of Oncology
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab, axitinib in gastrointestinal stromal tumor (GIST), sponsored by Maria Skłodowska-Curie National Research Institute of Oncology. Started Apr 2019; status: completed.
02
Drugs
avelumabaxitinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04258956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258956.